We’ve recently updated our valuation analysis.

Lekta Therapy Valuation

Is LEK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LEK?

Other financial metrics that can be useful for relative valuation.

LEK key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does LEK's PB Ratio compare to its peers?

LEK PB Ratio vs Peers
The above table shows the PB ratio for LEK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average5x
KOO Kooth
3.5x32.2%UK£37.2m
DRDR MCI Onehealth Technologies
2.1x56.0%CA$46.6m
NVOS Novo Integrated Sciences
0.7xn/aUS$32.6m
D Dental Corporation
4.3xn/a฿2.2b
LEK Lekta Therapy
n/an/a€49.8m

Price-To-Book vs Peers: Insufficient data to calculate LEK's Price-To-Book Ratio vs. peers for valuation analysis.


Price to Earnings Ratio vs Industry

How does LEK's PE Ratio compare vs other companies in the European Healthcare Industry?

Price-To-Book vs Industry: Insufficient data to calculate LEK's Price-To-Book Ratio vs. industry for valuation analysis.


Price to Book Ratio vs Fair Ratio

What is LEK's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LEK PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ration/a
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate LEK's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LEK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LEK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LEK's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

  • Take a look at our analysis of LEK's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Lekta Therapy regulatory filings.